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Abstract
Background: Both genetic and environmental factors play a role in the pathogenesis of type 2 diabetes and
cardiovascular diseases. The magnitude of genetic and environmental influences may vary in different populations
and can be investigated by twin studies.
Methods: In this cross-sectional study, 101 (63 monozygotic and 38 dizygotic) adult twin pairs (n = 202; mean age:
44.3 ± 15.8 years) were investigated. Past medical history was recorded and physical examination was performed.
Fasting venous blood samples were taken for measuring laboratory parameters. For assessing heritability of 14
cardiovascular risk factors, the structural equation (A-C-E) model was used.
Results: The following risk factors were highly (> 70.0%) or moderately (50.0 - 69.0%) heritable: weight (88.1%),
waist circumference (71.0%), systolic blood pressure (57.1%), diastolic blood pressure (57.7%), serum creatinine
(64.1%), fibrinogen (59.9%), and serum C-reactive protein (51.9%). On the other hand, shared and unique
environmental influences had the highest proportion of total phenotypic variance in serum total cholesterol (46.8%
and 53.2%), serum HDL-cholesterol (58.1% and 14.9%), triglycerides (0.0% and 55.9%), fasting blood glucose (57.1%
and 42.9%), fasting insulin (45.4% and 54.5%), serum uric acid (46.0% and 31.3%), and serum homocysteine (71.8%
and 28.2%, respectively).
Conclusion: Some cardiometabolic risk factors have strong heritability while others are substantially influenced by
environmental factors. Understanding the special heritability characteristics of a particular risk factor can
substantiate further investigations, especially in molecular genetics. Moreover, identifying genetic and
environmental contribution to certain cardiometabolic risk factors can help in designing prevention and treatment
strategies in the population investigated.
Keywords: cardiometabolic risk, diabetes mellitus, cardiovascular diseases, twin study, heritability, cardiovascular
prevention
Background
The term of cardiometabolic risk designates the global
risk for diabetes mellitus and cardiovascular diseases.
Beyond age, race, sex and family history, other classic
and newly recognized risk factors such as abnormal lipid
parameters, obesity, insulin resistance syndrome, smok-
ing, hypertension, hypercoagulation and inflammation
are globally covered by the term of cardiometabolic risk
[1]. Recently, the clinical usefulness of the metabolic
syndrome became questionable and instead of its use the
evaluation of global cardiometabolic risk has been widely
recommended [2,3].
Cardiometabolic risks in adulthood differ due to several
factors such as familial background, ethnicity, geographi-
cal areas, people’s life style and socioeconomic situation
[4]. Shortly, they are influenced by genetic and environ-
mental factors. As a result, the prevalence rate of cardio-
vascular diseases and type 2 diabetes mellitus may vary in
different populations. Unfortunately, people living in
Central European region are at increased risk for cardio-
vascular morbidity and mortality compared to other
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diabetes is in line with other European countries [6].
Genetic and environmental influences on cardiometa-
bolic risk factors can be investigated by twin studies.
Obviously, understanding the influences of genetic and
environmental factors would provide insights into the
pathomechanism of type 2 diabetes and cardiovascular
diseases. Moreover, the effectiveness of different treat-
ments might be anticipated more correctly knowing the
influence of genetic and environmental factors on cardi-
ometabolic risk factors.
In our classical twin study, 14 different risk factors
were simultaneously assessed in monozygotic (MZ) and
dizygotic (DZ) adult twin pairs without diabetes and
known cardiovascular diseases in order to determine the
genetic and environmental influences on cardiometabolic
risk factors.
Methods
Patient cohort
In this cross-sectional twin study, 101 adult twin pairs (n =
202; women 72.3%; mean age 44.3 years, range 18-81
years) were investigated. As no population based twin reg-
istry is available in Hungary at present, participants were
recruited from national twin meetings and through adver-
tisements published in local newspapers. Exclusion criteria
included pregnancy, diabetes mellitus, myocardial infarc-
tion or regular alcohol consumption (more than 2 units
daily) in the past medical history and acute infection
within three weeks of measurement.
Anthropometric parameters (weight, height, waist cir-
cumference) were recorded and a complete physical
examination including blood pressure measurement in
sitting position was performed. Body mass index (BMI)
was calculated from the values of weight and height.
Waist circumference was measured conventionally [7].
Physical activity level was assessed by the standardized
method: subjects reported the amount of time spent on
five different intensity levels of physical activity on an
average weekday as a total 24 h, then values of daily
metabolic equivalent score (MET) were derived and used
for statistical analysis [8]. Smoking habit was assessed as
smoking years while alcohol consumption was evaluated
as unit per week. Fasting venous blood samples were
taken from twin pairs and routine laboratory methods
were used for measuring laboratory parameters. The
value of homeostasis model assessment - insulin resis-
tance (HOMA-IR) was calculated using the widely
accepted formula [9]: HOMA-IR = fasting blood glucose
(mmol/l) × fasting insulin (μU/ml)/22.5.
Due to the lack of genotyping data of subjects, we used
a multiple self-reported question approach to assess zyg-
osity in order to maximize the accuracy of classification.
The most likely zygosity was assigned based on the seven
self-reported responses [10]. In this way, 63 MZ and 38
DZ twin pairs were investigated.
All participants provided informed consent. The investi-
gation was approved by the National Research Ethics
Committee (ETT TUKEB, Budapest) and was conducted
according to the principles expressed in the Declaration of
Helsinki. Participants were informed about the results of
the investigation and medical advice was provided when
needed.
Statistics
Descriptive statistical analysis was used for characterizing
MZ and DZ twin pairs. The differences in clinical and
laboratory findings between MZ and DZ twin pairs were
evaluated by using Mann-Whitney test. The level of sig-
nificance was set at p < 0.05.
Bivariate correlation between the same age- and gen-
der-corrected parameters was separately analyzed in MZ
and DZ pairs. If coefficients of correlations (r values)
were high in MZ and not in DZ pairs, a genetic effect
could be assumed. On the other hand, if r values were
lower or close to each other when MZ and DZ pairs
were compared, an environmental effect could be
supposed.
For assessing heritability, a structural equation model,
often called the A-C-E model, was used. In this model,
three latent variables, additive genetic effects (“A”), com-
mon (or shared) environment (“C”) and unshared (or
unique) environment (“E”) drive the variance in the phe-
notype for each twin [11]. “A” is perfectly (1.0) correlated
across MZ twins and 0.5 correlated across DZ twins. “C”
is perfectly correlated independently of zygosity. “E” is
uncorrelated across co-twins. Since measurement error in
the phenotype is also uncorrelated across measurements,
it appears as part of the unique environmental component.
Considering the well established, reliable measures used in
this study this property of the model is of little concern.
Empirically derived bootstrapped confidence intervals are
presented for the heritability and environmental propor-
tion estimates [12]. All inferential statistics were estimated
using full information maximum likelihood with the soft-
ware Mplus Version 6 [13].
For each phenotype two A-C-E models were esti-
mated. Model-1 corrects for the twins’ age and gender.
The correction for age and gender is justified by gender
being 100% genetic and age being 100% environmental.
All other predictors could carry both a genetic and an
environmental component. Results from Model-1 tell us
the total genetic and environmental impact on the
dependent variable. Model-2, in addition to age and
gender, also corrects for BMI and waist circumference.
Making a comparison of results in Model-1 and Model-
2 analysis, effect of BMI and waist circumference on the
phenotypic variance could be evaluated.
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ence was considered high if > 70% of the total variance
was related to additive genetic factors (“A”). Genetic
influence was designated as moderate if additive genetic
factors (“A”) contributed between 50.0% and 69.0% to
the total variance of phenotype measured. If genetic
influence was < 50.0% environmental factors have sub-
stantial impact on the phenotypic variance.
Heritability of calculated parameters (BMI, HOMA-IR,
estimated glomerular filtration rate [eGFR]) was not
investigated. Instead, heritability of their components
(weight, height, fasting blood glucose, fasting insulin,
serum creatinine) was analyzed only.
Results
Although a significant difference between ages of MZ ver-
sus DZ twin pairs occurred, there were no significant dif-
ferences between gender, anthropometric parameters,
smoking and drinking habits as well as physical activity.
As for other cardiovascular risk factors, systolic blood
pressure, serum total cholesterol and triglycerides values
were significantly higher in MZ versus DZ twin pairs. No
significant differences were found between diastolic blood
pressure and other laboratory parameters when MZ and
DZ twins were compared (Table 1.)
Assessing bivariate correlation between age- and gen-
der-corrected parameters measured separately in MZ
and DZ twin pairs, the coefficients of correlation
(r values) were high for anthropometric parameters,
blood pressure, serum creatinine, fibrinogen and high
sensitivity C-reactive protein (hsCRP) values in MZ
t w i n sw h e r e a st h o s ef o rt h es a m em e a s u r e m e n t sw e r e
much lower in DZ twins. As for serum total cholesterol,
triglycerides, HDL-cholesterol, fasting blood glucose,
fasting insulin, serum uric acid and homocysteine values,
the co-twin correlation was not so strong or r values
were very close to each other for both zygosity groups
(Table 2).
Using the structural equation model, the following risk
factors were highly or moderately heritable: weight (88.1%;
95% CI: 66.0-94.0), waist circumference (71.0%; 95% CI:
17.7-91.8), systolic blood pressure (57.1%; 95% CI: 27.4-
73.5), diastolic blood pressure (57.7%; 95% CI: 23.7-74.4),
serum creatinine (64.1%; 95% CI: 34.6-78.5), fibrinogen
(59.9%; 95% CI: 20.5-78.5), and serum hsCRP (51.9%; 95%
CI: 0.0-79.4). On the other hand, shared and unique envir-
onmental influences had the highest proportion of total
phenotypic variance in serum total cholesterol (46.8 and
53.2%), serum HDL-cholesterol (58.1 and 14.9%), triglycer-
ides (0.0% and 55.9%), fasting blood glucose (57.1 and
Table 1 Clinical and laboratory findings of 63 monozygotic (MZ) and 38 dizygotic (DZ) twin pairs (x ± SD or %)
MZ twins
(n = 126)
DZ twins
(n = 76)
p value
Women (%) 73.0 71.1 0.832
Age (years) 47.4 ± 15.5 38.3 ± 13.5 < 0.001
Duration of smoking (years) 4.8 ± 9.5 4.8 ± 9.6 0.829
Alcohol consumption (unit/week) 1.1 ± 2.2 1.9 ± 3.4 0.553
Physical activity (MET/24 hours) 65.8 ± 22.2 60.3 ± 21.1 0.094
Weight (kg) 71.1 ± 14.5 72.4 ± 17.6 0.827
Height (cm) 165 ± 9 167 ± 9 0.211
Body mass index (kg/m
2) 25.9 ± 4.9 25.8 ± 5.9 0.576
Waist circumference (cm) 88 ± 14 88 ± 16 0.757
Systolic blood pressure (mmHg) 130.2 ± 14.8 125.3 ± 14.1 0.026
Diastolic blood pressure (mmHg) 74.7 ± 10.3 72.6 ± 9.8 0.152
Serum total cholesterol (mmol/l) 5.35 ± 1.23 5.00 ± 1.07 0.031
Serum HDL-cholesterol (mmol/l) 1.60 ± 0.39 1.60 ± 0.36 0.755
Serum triglycerides (mmol/l) 1.33 ± 0.86 1.07 ± 0.80 0.004
Fasting blood glucose (mmol/l) 5.01 ± 0.75 4.81 ± 0.63 0.064
Fasting insulin (μU/ml) 7.35 ± 5.15 6.83 ± 4.64 0.665
HOMA-IR 1.70 ± 1.39 1.53 ± 1.29 0.404
Serum creatinine (μmol/l) 70.0 ± 9.8 72.3 ± 11.4 0.219
Serum uric acid (μmol/l) 286.3 ± 75.3 282.2 ± 74.8 0.584
Fibrinogen (g/l) 3.27 ± 0.69 3.18 ± 0.72 0.219
Serum homocysteine (μmol/l) 12.1 ± 5.64 10.9 ± 2.9 0.408
Serum C-reactive protein (mg/l) 3.82 ± 6.53 4.27 ± 5.01 0.871
MET: metabolic equivalent score
HOMA-IR: homeostatis model assessment insulin resistance
Jermendy et al. Cardiovascular Diabetology 2011, 10:96
http://www.cardiab.com/content/10/1/96
Page 3 of 842.9%), fasting insulin (45.4 and 54.5%), serum uric acid
(46.0 and 31.3%), and serum homocysteine (71.8 and
28.2%, respectively) (Figure 1). Comparing the results of
the initial and final analysis (Model-1 and Model-2), the
difference in A-C-E model varied from 0.0% to 17.1%,
indicating that only a minor proportion of the influences
can be explained by the effects of anthropometric para-
meters (Table 3).
Discussion
Several cardiometabolic risk factors (weight, waist cir-
cumference, blood pressure, serum creatinine, fibrinogen
Table 2 Bivariate correlation (r values and 95% CI) between age- and gender-corrected parameters measured in
monozygotic (MZ) and dizygotic (DZ) twin pairs
MZ twins
(n = 126; 63 twin pairs)
DZ twins
(n = 76; 38 twin pairs)
r value 95% CI r value 95% CI
Weight 0.881 0.800-0.931 0.437 0.077-0.737
Waist circumference 0.865 0.763-0.935 0.510 0.052-0.781
Systolic blood pressure 0.598 0.426-0.731 0.055 -0.524-0.576
Diastolic blood pressure 0.608 0.444-0.728 0.147 -0.321-0.648
Serum total cholesterol 0.445 0.259-0.633 0.640 0.363-0.845
Serum HDL-cholesterol 0.840 0.626-0.895 0.658 -0.293-0.798
Serum triglycerides 0.527 0.281-0.707 0.349 -0.023-0.625
Fasting blood glucose 0.523 0.453-0.804 0.545 0.068-0.744
Fasting insulin 0.513 0.292-0.725 0.492 0.209-0.716
Serum creatinine 0.639 0.479-0.784 0.159 -0.065-0.434
Serum uric acid 0.691 0.542-0.799 0.629 0.453-0.772
Fibrinogen 0.663 0.499-0.791 0.322 0.024-0.639
Serum homocysteine 0.681 0.505-0.781 0.838 0.582-0.948
Serum C-reactive protein 0.683 0.460-0.851 0.138 -0.199-0.555
Figure 1 Mean values of additive genetic (A), common (C) and unique environmental (E) influences on cardiometabolic risk factors
(univariate structural equation model [A-C-E] analysis in 101 twin pairs). Weight and waist circumference are corrected for age and
gender. All other values are corrected for age, gender, waist circumference and BMI.
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in our Hungarian twin cohort while others (serum total
cholesterol, HDL-cholesterol, triglycerides, fasting blood
glucose, fasting insulin, serum uric acid and homocys-
teine) were substantially influenced by shared and
unique environmental factors.
The pathomechanism of atherosclerosis is a complex
process involving several traditional and novel cardiovas-
cular risk factors. In this respect, both genetic and envir-
onmental factors can be identified. Recently, the term of
cardiometabolic risk is widely used for risk factors contri-
buting to both cardiovascular and metabolic diseases [1].
Clearly, cardiovascular diseases and type 2 diabetes are
believed to be multifactorial in origin indicating that
many genes alone or in combination with environmental
factors contribute to the development of the phenotypic
variance. Classical twin studies, such as ours, can help to
estimate the genetic and environmental components of
variance of the traits.
It is well documented that beyond weight (BMI), waist
circumference, blood pressure, serum lipids and blood glu-
cose [14,15], serum creatinine (eGFR) [16], serum uric
acid [17], fibrinogen [18], homocysteine [19] and hsCRP
[20] could also be considered as cardiovascular or cardio-
metabolic risk factors. Fasting insulin could be a sign of
hyperinsulinaemia or insulin resistance and may contri-
bute to cardiometabolic risk [ 2 1 ] .I nc o n t r a s tt oo t h e r s
[15], heritability of BMI, HOMA-IR, eGFR and that of the
metabolic syndrome was not assessed in our study because
heritability of calculated values has no or limited biological
relevance. As for the metabolic syndrome, its clinical use-
fulness is widely debated and the term is considered rather
an educational concept than a practical tool in the diagno-
sis and treatment [2,3]. Therefore, heritability of the meta-
bolic syndrome components was analyzed only in our
study.
The strong heritability of anthropometric parameters
(weight, waist circumference) in our cohort is in line
Table 3 Parameter estimates for additive genetics (A), common environmental (C) and unique environmental (E)
influences on cardiometabolic risk factors (A-C-E univariate model analysis)
Parameter estimates
„A” Additive genetics
(95% CI)
„C” Common environmental
(95% CI)
„E” Unique environmental
(95% CI)
Weight Model-1 88.1% (66.0 - 94.0) 0.0% (0.0 - 56.8) 11.9% (6.9 - 20.1)
Waist circumference Model-1 71.0% (17.7 - 91.8) 15.5% (0.0 - 68.0) 13.5% (6.5 - 23.9)
Systolic blood pressure Model-l 59.0% (35.6 - 74.1) 0.0% (0.0 - 0.0) 41.0% (26.5 - 58.2)
Model-2 57.1% (27.4 - 73.5) 0.0% (0.0 - 65.9) 42.9% (28.9 - 61.1)
Diastolic blood pressure Model-1 60.4% (25.0 - 75.0) 0.0% (0.0 - 36.2) 39.6% (26.5 - 55.8)
Model-2 57.7% (23.7 - 74.4) 0.0% (0.0 - 65.6) 42.3% (27.8 - 60.2)
Serum total cholesterol Model-1 0.0% (0.0 - 65.5) 50.1% (35.6 - 65.5) 49.9% (33.7 - 64.8)
Model-2 0.0% (0.0 - 70.2) 46.8% (30.4 - 64.2) 53.2% (35.8 - 69.3)
Serum HDL-cholesterol Model-1 36.4% (3.9 - 69.5) 47.6% (14.9 - 71.9) 16.0% (9.4 - 23.1)
Model-2 27.1% (0.0 - 62.1) 58.1% (25.1 - 81.8) 14.9% (8.3 - 23.0)
Serum triglycerides Model-1 35.6% (0.0 - 68.6) 17.1% (0.0 - 56.7) 47.3% (28.9 - 66.9)
Model-2 44.1% (22.2 - 65.1) 0.0% (0.0 - 0.0) 55.9% (34.8 - 77.6)
Fasting blood glucose Model-1 0.0% (0.0 - 57.8) 53.1% (34.8 - 69.3) 46.9% (33.6 - 61.2)
Model-2 0.0% (0.0 - 34.4) 57.1% (36.4 - 74.8) 42.9% (28.4 - 59.8)
Fasting insulin Model-1 4.2% (0.0 - 60.4) 47.1% (18.1 - 69.0) 48.7% (30.1 - 67.8)
Model-2 0.1% (0.0 - 62.8) 45.4% (13.6 - 68.1) 54.5% (34.2 - 77.6)
Serum creatinine Model-1 62.3% (44.9 - 78.4) 0.0% (0.0 - 0.0) 37.7% (21.6 - 53.9)
Model-2 64.1% (34.6 - 78.5) 0.0% (0.0 - 56.2) 35.9% (22.2 - 51.8)
Serum uric acid Model-1 12.4% (0.0 - 48.1) 56.7% (25.7 - 74.2) 30.9% (20.5 - 45.8)
Model-2 22.7% (0.0 - 74.5) 46.0% (0.0 - 71.8) 31.3% (18.6 - 46.1)
Fibrinogen Model-1 66.2% (41.1 - 83.5) 0.0% (0.0 - 25.1) 33.8% (20.8 - 50.3)
Model-2 59.9% (20.5 - 78.5) 3.4% (0.0 - 57.7) 36.7% (23.0 - 57.3)
Serum homocysteine Model-1 0.0% (0.0 - 69.9) 72.4% (53.7 - 80.6) 27.6% (19.4 - 45.1)
Model-2 0.0% (0.0 - 46.9) 71.8% (50.5 - 79.7) 28.2% (20.3 - 47.9)
Serum C-reactive protein Model-1 66.0% (26.0 - 87.0) 0.0% (0.0 - 43.4) 34.0% (15.0 - 59.1)
Model-2 51.9% (0.0 - 79.4) 0.0% (0.0 - 52.4) 48.1% (20.7 - 81.6)
Model-1: values corrected for age and gender
Model-2: values corrected for age, gender, waist circumference and body mass index
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genetic determination of systolic and diastolic blood
pressure values in our study corresponds to other clini-
cal observation [23]. As for lipid parameters, heritability
varied between 8-72% for total cholesterol, 21-79% for
HDL-cholesterol and 19-72% for serum triglycerides in
different studies [15]. Our results (heritability < 50%)
corroborate the importance of environmental influences.
The environmental determination of fasting blood glu-
cose and fasting insulin in our study is in accordance
with observation of others [15].
Several clinical studies documented that cardiovascular
morbidity and mortality are associated with chronic kidney
diseases characterized by elevated serum creatinine and
decreasing eGFR values [16]. In our study, genetic factors
had moderate influence (64.1%) on serum creatinine value.
This is in line with results of other twin or family studies
[24-26].
Serum uric acid should be considered as an independent
cardiovascular risk factor [17]. No dominant genetic influ-
ence (22.7%) on serum uric acid values was found in our
cohort. In a recent study [27], genetic determination of
s e r u mu r i ca c i dv a l u e sw a sf o u n dt ob e4 2 %w h i l et h i s
number varied from 40% to 73% in other studies reviewed.
The level of fibrinogen can reflect to hypercoagulation
and is considered among cardiovascular risk factors [18].
The moderate genetic influence (59.9%) on phenotypic
variance of fibrinogen in our study is in line with earlier
observations [28].
Homocysteine is listed among the relatively newer cardi-
ovascular risk factors [19], although the results of inter-
ventional studies proved to be disappointing [29]. In our
study, the value of serum homocysteine was influenced by
both shared and unique environmental factors (71.8% and
28.2%, respectively). This observation corroborates the
findings from Cesari et al [30]. It is of note, however, that
strong heritability was reported by others [31,32].
The value of hsCRP is a marker of low grade inflamma-
tion and is recently considered as a cardiovascular risk fac-
tor both in epidemiological and interventional studies [18].
A moderate heritability (51.9%) in hsCRP value was found
in our twin cohort, similarly to others [33].
Taken our results together, it is obvious that some
minor discrepancies in numerical genetic and environ-
mental influences on cardiometabolic risk factors exist
when our results are compared to those of formerly per-
formed twin studies. However, it is not a surprise because
different populations were investigated. It is of note, there-
fore, that our results shouldb ec o n s i d e r e dv a l i do n l yi n
Hungarian adult people without diabetes and cardiovascu-
lar diseases.
Beyond classical twin studies [34], the pathomechan-
ism, especially the genetic susceptibility to cardiovascular
diseases, could also be investigated by methods of
molecular genetics [35]. Recently, some aspects of cardio-
metabolic disease heritability were highlighted by gene
association studies. This was the case for type 2 diabetes
and the metabolic syndrome [36-38] but functional gene
variants were observed also in hypertension [39] and in
lipid abnormalities [40]. More importantly, developments
in molecular genetics and pharmacogenetics have already
resulted in better understanding of the underlying patho-
mechanism of certain cardiometabolic diseases providing
the possibility of disease prevention or individualized
therapies for affected patients in the future [41].
If a cardiometabolic risk factor proved to be highly or
moderately heritable it does not mean that the phenotype
cannot be influenced. Rather, early and sustained interven-
tion is needed. Clearly, if a risk factor has strong heritabil-
ity, beneficial effect of any intervention can only be
successful if it is implemented in early adulthood or, even
better, in early childhood. In addition, recent progress in
molecular genetics and pharmacogenetics holds the pro-
mise of individualized therapies for patients carrying dis-
ease predisposing genotypes [42]. On the contrary, it can
be assumed that a risk factor with substantial environmen-
tal determination can much easily be affected by changes
in environments. Nevertheless, the individual variation in
the result of intervention may be high.
Our study has some limitations. The sample size was
modest but comparable to other clinical studies with twins
[28]. The zygosity in our twin cohort was classified accord-
ing to validated questionnaires. Nevertheless, this method
is widely accepted in clinically oriented twin studies [10].
Our results were derived from a healthy adult twin popu-
lation, therefore, the extrapolation of our findings to
patients with clinically manifest cardiovascular diseases or
diabetes has some limitations. Although diabetes mellitus
and myocardial infarction in the past medical history were
considered as exclusion criteria, oral glucose tolerance test
and detailed cardiological investigations were not carried
out in our cohort.
The strengths of our study are worth mentioning. All
subjects were investigated by the same investigators (JO,
RS, ÁLJ, ÁDT, DLT) in one department (Bajcsy-Zsilinszky
Hospital). All laboratory parameters were centrally mea-
sured in the same hospital immediately after taking venous
blood sample. In our study, 14 cardiometabolic risk factors
were simultaneously evaluated. The number of twin stu-
dies evaluating heritability of different cardiometabolic risk
factors in such a large scale is limited [15,43]. To the best
of our knowledge this is the first twin study from Hungary
evaluating heritability of different cardiometabolic risk
factors.
Conclusions
Our study indicated that the influence of genetic and
environmental factors on cardiometabolic risk factors’
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them have strong heritability while others are substan-
tially influenced by environmental factors. The better
understanding of genetic and environmental contribu-
tion to certain cardiometabolic risk factors can help in
designing prevention and treatment strategies in the
population investigated.
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